ESR1 and cancer: Experimental in vivo studies in models of cancers with genetic or pharmacological manipulation of specific estrogen receptors have demonstrated that estrogen/anti-estrogen activity can exert meaningful net effects on the stromal cells in vivo (e.g., [42,155]).